Literature DB >> 32386603

Detection of the 'Big Five' mold killers of humans: Aspergillus, Fusarium, Lomentospora, Scedosporium and Mucormycetes.

Christopher R Thornton1.   

Abstract

Fungi are an important but frequently overlooked cause of morbidity and mortality in humans. Life-threatening fungal infections mainly occur in immunocompromised patients, and are typically caused by environmental opportunists that take advantage of a weakened immune system. The filamentous fungus Aspergillus fumigatus is the most important and well-documented mold pathogen of humans, causing a number of complex respiratory diseases, including invasive pulmonary aspergillosis, an often fatal disease in patients with acute leukemia or in immunosuppressed bone marrow or solid organ transplant recipients. However, non-Aspergillus molds are increasingly reported as agents of disseminated diseases, with Fusarium, Scedosporium, Lomentospora and mucormycete species now firmly established as pathogens of immunosuppressed and immunocompetent individuals. Despite well-documented risk factors for invasive fungal diseases, and increased awareness of the risk factors for life-threatening infections, the number of deaths attributable to molds is likely to be severely underestimated driven, to a large extent, by the lack of readily accessible, cheap, and accurate tests that allow detection and differentiation of infecting species. Early diagnosis is critical to patient survival but, unlike Aspergillus diseases, where a number of CE-marked or FDA-approved biomarker tests are now available for clinical diagnosis, similar tests for fusariosis, scedosporiosis and mucormycosis remain experimental, with detection reliant on insensitive and slow culture of pathogens from invasive bronchoalveolar lavage fluid, tissue biopsy, or from blood. This review examines the ecology, epidemiology, and contemporary methods of detection of these mold pathogens, and the obstacles to diagnostic test development and translation of novel biomarkers to the clinical setting.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aspergillosis; Aspergillus; Fungal diagnostics; Fusarium; Lateral-flow device; Lomentospora; Monoclonal antibody; Mucormycosis; Mycoses; Scedosporium

Mesh:

Year:  2019        PMID: 32386603     DOI: 10.1016/bs.aambs.2019.10.003

Source DB:  PubMed          Journal:  Adv Appl Microbiol        ISSN: 0065-2164            Impact factor:   5.086


  10 in total

1.  Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections.

Authors:  Michael A Pfaller; Cecilia G Carvalhaes; Sean DeVries; Paul R Rhomberg; Mariana Castanheira
Journal:  Med Mycol       Date:  2022-05-06       Impact factor: 3.747

2.  A case of bilateral injection abscesses caused by Graphium type of Scedosporium apiospermum.

Authors:  Sravanti K; Pravalika B; Pavani M; Ashwini M; Lakshmi V
Journal:  Med Mycol Case Rep       Date:  2022-05-14

3.  zzm321990 Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology.

Authors:  Genna Davies; Oski Singh; Juergen Prattes; Martin Hoenigl; Paul W Sheppard; Christopher R Thornton
Journal:  J Fungi (Basel)       Date:  2020-12-31

4.  Antibody-guided in vivo imaging of Aspergillus fumigatus lung infections during antifungal azole treatment.

Authors:  Sophie Henneberg; Anja Hasenberg; Andreas Maurer; Franziska Neumann; Lea Bornemann; Irene Gonzalez-Menendez; Andreas Kraus; Mike Hasenberg; Christopher R Thornton; Bernd J Pichler; Matthias Gunzer; Nicolas Beziere
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

Review 5.  Highlights of the Latest Developments in Radiopharmaceuticals for Infection Imaging and Future Perspectives.

Authors:  Ekaterina Dadachova; Drauzio E N Rangel
Journal:  Front Med (Lausanne)       Date:  2022-02-11

Review 6.  Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.

Authors:  Rohit Sharma; Praveen Kumar; Abdur Rauf; Ashun Chaudhary; Pradeep Kumar Prajapati; Talha Bin Emran; Clara Mariana Gonçalves Lima; Carlos Adam Conte-Junior
Journal:  Front Cell Infect Microbiol       Date:  2022-07-18       Impact factor: 6.073

7.  Development of a Monoclonal Antibody and a Serodiagnostic Lateral-Flow Device Specific to Rhizopus arrhizus (Syn. R. oryzae), the Principal Global Agent of Mucormycosis in Humans.

Authors:  Genna E Davies; Christopher R Thornton
Journal:  J Fungi (Basel)       Date:  2022-07-21

8.  Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).

Authors:  Michael A Pfaller; Cecilia G Carvalhaes; Paul Rhomberg; Shawn A Messer; Mariana Castanheira
Journal:  J Antibiot (Tokyo)       Date:  2021-06-30       Impact factor: 2.649

9.  Biochemical and structural studies of target lectin SapL1 from the emerging opportunistic microfungus Scedosporium apiospermum.

Authors:  Dania Martínez-Alarcón; Viviane Balloy; Jean-Philippe Bouchara; Roland J Pieters; Annabelle Varrot
Journal:  Sci Rep       Date:  2021-08-09       Impact factor: 4.379

Review 10.  Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes.

Authors:  Omer Sefvan Janjua; Muhammad Saad Shaikh; Muhammad Amber Fareed; Sana Mehmood Qureshi; Muhammad Ikram Khan; Danya Hashem; Muhammad Sohail Zafar
Journal:  J Fungi (Basel)       Date:  2021-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.